Windtree Therapeutics, Inc. (WINTW)
Chart Events
Performance Outlook
| Previous Close | 0.5000 |
| Open | 0.3850 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.3450 - 0.4900 |
| 52 Week Range | 0.3450 - 0.4900 |
| Volume | |
| Avg. Volume | N/A |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for WINTW
Related Research
- GlobeNewswire
Windtree Therapeutics Reports Second Quarter 2022 Financial Results and Provides Key Business Updates
WARRINGTON, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today reported financial results for the second quarter ended June 30, 2022 and provided key business updates. “Since announcing the positive topline results from our Phase 2 SEISMiC study of istaroxime in early cardiogenic shock, we have received notable interest and posit
- GlobeNewswire
Windtree Is Leveraging Positive Istaroxime Early Cardiogenic Shock Results to Proactively Engage in Licensing Discussions and Explore Strategic Opportunities to Realize Greater Shareholder Value
Positive Data for Istaroxime in Early Cardiogenic Shock Brings Notable Interest from Potential Partners WARRINGTON, Pa., June 29, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for acute cardiovascular disorders, today provided an update to its strategy and pursuit related to partnerships and transactions. During the second quarter, Windtree announced positive clinical results for istaroxime in early ca
- GlobeNewswire
Windtree Presents Data from its Positive SEISMiC Phase 2 Study of Istaroxime in Early Cardiogenic Shock in a Late-Breaker Presentation at the European Society of Cardiology Heart Failure Meeting in Madrid
The study met its primary endpoint of improved systolic blood pressure (SBP) profile at 6 hours with the istaroxime group performing significantly better than the control group Increased SBP also persisted through 24 hours The study also met several key secondary endpoints associated with improving cardiac function Investor conference call and webcast to be held today, Monday May 23 at 4:30 pm EDT WARRINGTON, Pa., May 23, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a b
